ClinicalTrials.gg

Neutropenia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 316 studies for Neutropenia across more than 10 countries. 42 are recruiting or about to start. 109 of them are mainly about Neutropenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Febrile Neutropenia too: 429 studies, 72 open.

Status

Completed
209
Status unknown
36
Recruiting
24
Terminated
17
Not yet recruiting
17
Withdrawn
8

Phase

Phase 2
101
Phase 3
63
Phase 1
54
Phase 4
28
Early Phase 1
1

Where

United States
110
China
42
France
21
Korea, Republic of
17
Germany
15
Canada
15

Who develops what

Add Neutropenia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pegfilgrastimEarlier only
Evidence
  • NCT04345900 · BeyondSpring Pharmaceuticals Inc. · Phase 2 · comparator · “Pegfilgrastim” · registered Mar 2020
  • NCT03559387 · Prolong Pharmaceuticals · Phase 2 · comparator · “Neulasta®” · registered May 2018
  • NCT03294577 · BeyondSpring Pharmaceuticals Inc. · Phase 3 · live · comparator · “Pegfilgrastim” · registered Sep 2017
  • NCT03252431 · EVIVE Biotechnology · Phase 3 · comparator · “Neulasta” · registered Aug 2017
  • NCT03102606 · BeyondSpring Pharmaceuticals Inc. · Phase 3 · comparator · “Pegfilgrastim” · registered Mar 2017
Amgen29% of its industry studiesUS: Amgen (FDA 2002) + 7 othersEU: Amgen (EMA 2002) + 12 others00 studies
DocetaxelEarlier only
Evidence
  • NCT03294577 · BeyondSpring Pharmaceuticals Inc. · Phase 3 · live · background · “Docetaxel, doxorubicin, and cyclophosphamide (TAC)” · registered Sep 2017
  • NCT02953340 · Zydus Lifesciences Limited · Phase 3 · background · “Docetaxel” · registered Oct 2016
  • NCT02643420 · Zydus Lifesciences Limited · Phase 3 · background · “Docetaxel” · registered Dec 2015
  • NCT01724866 · Zydus Lifesciences Limited · Phase 2 · background · “Docetaxel” · registered Oct 2012
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized00 studies
FilgrastimEarlier only
Evidence
  • NCT04174599 · EVIVE Biotechnology · Phase 3 · comparator · “GRAN®” · registered Jul 2019
  • NCT03343145 · dong a st · Phase 3 · comparator · “Neupogen 5µg/kg/day” · registered Nov 2017
  • NCT02104830 · Biocad · Phase 3 · comparator · “Filgrastim” · registered Apr 2014
  • NCT01569087 · Biocad · Phase 2 · comparator · “filgrastim” · registered Mar 2012
  • NCT01519700 · Novartis · Phase 3 · comparator · “Filgrastim” · registered Jan 2012
Pfizer15% of its industry studiesUS: SICOR BIOTECH (FDA 2012) + 4 others00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Jun 2027 est.Albipagrastim alf · Qilu Pharmaceutical Co., Ltd. · Phase 2 named, not the main aimNCT07724756 Phase II Study of QLC2519 in Pediatric Solid Tumor Participants — primary endpoint: Cmax of QLC2519 · 18 enrolled
  • Sep 2027 est.mavorixafor · X4 Pharmaceuticals · Phase 3 main aimNCT06056297 A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections — primary endpoint: Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period · 176 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neutropenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 1 open · Beta-lactamase inhibitors 1 open · Antimitotic agents 7 · Alkylating agents 7

Coming up

12studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger. 11 (46%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (4%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
109 (38%)9 (38%)
1820 (83%)20 (83%)
3016 (67%)16 (67%)
4016 (67%)16 (67%)
5016 (67%)16 (67%)
6516 (67%)16 (67%)
7514 (58%)14 (58%)
8512 (50%)12 (50%)

Across all 316 studies, recruiting or not: 38% stop at 75 or younger and 24% at 65; 34% take children; 12% are for women only and 1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neutropenia studies take

Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 229 mo11–41 · 25 studies——
Phase 320 mo11–34 · 16 studies——
Interventional, no phase31 mo26–40 · 14 studies——
Observational43 mo18–190 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 316. Browse all 316 → or search them.